Login to Your Account

Clinic Roundup

Thursday, April 11, 2013

• Photocure ASA, of Oslo, Norway, reported final results from its Phase IIb study of Cevira in patients with human papillomavirus (HPV)-related disease of the cervix, showing that the drug-delivery device demonstrated significant and sustained efficacy in the eradication of oncogenic HPV infections and precancerous lesions in CIN2 patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription